Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet

NCT06557772 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06557772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06557772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 29, 2024
Completion date
April 10, 2029
Enrollment
229 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease, coeliac disease